Editorial illustration for Bristol Myers Squibb Builds SuperDuperPOD on NVIDIA Vera Rubin
Bristol Myers Squibb Builds AI Drug Discovery SuperPOD
Bristol Myers Squibb Builds SuperDuperPOD on NVIDIA Vera Rubin
Bristol Myers Squibb is putting eight NVIDIA DGX Vera Rubin NVL72 systems to work on drug discovery, a second SuperPOD deployment that the pharmaceutical company says will be the most powerful and energy-efficient AI cluster in life sciences. The setup, built on NVIDIA's new Vera CPUs and Rubin GPUs, delivers up to 10 times the performance per megawatt of the infrastructure it's replacing. BMS already runs one of the largest AI clusters in the industry. This move adds to it rather than starts from scratch.
The system will run NVIDIA's BioNeMo Agent Toolkit alongside a unified AI platform covering predictions, model training and agentic workflows across the drug discovery pipeline. The goal, according to BMS staff involved in the rollout, is to stop rationing compute among a handful of favored researchers and instead give every scientist at the company the same access. That shift, from scarcity to open supply, is meant to compress research cycles and widen the chemical spaces scientists can realistically explore.
Erin Davis, BMS vice president of research business insights and technology, has a name for the new cluster. She calls it the "SuperDuperPOD," a label that doubles as a description of both scale and ambition.
What Davis and other top BMS researchers are really after is what that access makes possible: faster cycles, bigger chemical spaces and a full drug discovery pipeline where researchers think about the science, not the logistics of lining up resources.
Why this matters
BMS isn't a chipmaker or a cloud vendor talking up hypothetical demand. It's a drugmaker putting eight DGX Vera Rubin NVL72 systems behind actual discovery work, and that's a useful signal for anyone trying to gauge whether Vera Rubin is real or just Jensen Huang's next slide. Pharma has money, patience, and a genuine bottleneck problem in target identification and molecule screening, so if a "SuperDuperPOD" produces faster hit rates or shorter trial timelines, that's a much harder data point to wave away than another benchmark chart.
For researchers and founders building AI tools for biotech, this is also a preview of what infrastructure competitors will expect access to soon. Worth watching: whether BMS publishes anything concrete about output, not just cluster specs, and whether NVIDIA can actually ship Vera Rubin at volume to the rest of the industry, rather than a handful of flagship deployments used for marketing. Naming your supercomputer is easy.
Proving it changes drug discovery timelines is the part that still needs showing.
Related Reading
Business & Startups Nordic pilot adds Gemini for Education, NotebookLM to boost AI literacy
Business & Startups Kling launches Video O1, all-in-one model with MVL bridge using transformer
Business & Startups DeepSeek Seeks More Capital Weeks After USD 7B Funding Round
Related Topic NVIDIA and Google Cloud let developers scale AI from prototype to production
Market Trends
Related Topic NVIDIA NeMo powers telco reasoning model for autonomous network workflows
Industry Applications
From Archives OpenAI's Miles Wang in Talks for USD 2B AI Drug Discovery Startup
From Archives Anthropic's New AI Ad Campaign Draws Criticism for 'Creepy' Tactics
From Archives NVIDIA TAO Agent Skills Accelerate Vision Model Post-Training
Research & Benchmarks
From Archives NVIDIA Decoding Cuts Color Code Error Rates by Over 300X
Market Trends
Common Questions Answered
What is the SuperDuperPOD that Bristol Myers Squibb built on NVIDIA Vera Rubin?
The SuperDuperPOD is a deployment of eight NVIDIA DGX Vera Rubin NVL72 systems that Bristol Myers Squibb constructed for drug discovery applications. According to the company, it represents the most powerful and energy-efficient AI cluster in life sciences, delivering up to 10 times the performance per megawatt compared to the infrastructure it replaced.
How does the new NVIDIA Vera Rubin infrastructure improve upon Bristol Myers Squibb's previous AI cluster?
The new setup built on NVIDIA's Vera CPUs and Rubin GPUs delivers significantly better energy efficiency and performance metrics than the previous system. This second SuperPOD deployment adds to BMS's already existing one of the largest AI clusters in the pharmaceutical industry, enhancing their computational capabilities for drug discovery work.
What specific benefits does the SuperDuperPOD provide to BMS researchers in drug discovery?
The enhanced AI infrastructure enables faster research cycles, allows exploration of bigger chemical spaces, and creates a complete drug discovery pipeline where researchers can focus on the science rather than managing resource logistics. This improved access to computational power represents a meaningful advancement in how BMS can conduct target identification and molecule screening.
Why is Bristol Myers Squibb's adoption of NVIDIA Vera Rubin significant for the industry?
BMS is a pharmaceutical company with genuine bottleneck problems in drug discovery, not a chipmaker or cloud vendor making theoretical claims about demand. Their real-world deployment of eight DGX Vera Rubin NVL72 systems provides credible evidence that the Vera Rubin technology can deliver practical benefits like faster hit rates and shorter trial timelines in actual drug discovery work.
Further Reading
- Bristol Myers Squibb Building Life Science Industry's Most Advanced AI Factory on NVIDIA Vera Rubin - NVIDIA Blogs
- Bristol Myers Squibb Deploys AI SuperPOD on NVIDIA Vera Rubin - TechBuzz AI
- Bristol Myers buys Nvidia's latest AI computing system for drug research - The Star
- First look at Nvidia's AI system Vera Rubin and how it beats Blackwell - CNBC
